CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients - Wikidata - wikimedia - TriplyDB

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

http://www.wikidata.org/entity/Q36951727

about

Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer?Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies Recent advances in T-cell engineering for use in immunotherapy Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors.Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia Immunotherapy in hematologic malignancies: past, present, and future.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults Masked Chimeric Antigen Receptor for Tumor-Specific Activation.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.Fully human CD19-specific chimeric antigen receptors for T-cell therapy.Toxicities of chimeric antigen receptor T cells: recognition and management.Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia Immunotherapy for opportunistic infections: Current status and future perspectives.Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.New development in CAR-T cell therapy.Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities Chimeric antigen receptor T-cell therapies for lymphoma.Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy.Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia Novel Immunotherapies for Multiple Myeloma.Recent developments in immunotherapy of acute myeloid leukemia.Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities.An Update on the Use of Immunotherapy in the Treatment of Lymphoma.CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.Adoptive T-Cell Therapy for Solid Tumors.Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.Recent advances in T-cell immunotherapy for haematological malignancies.Engineered T cells: the promise and challenges of cancer immunotherapy.Forecasting Cytokine Storms with New Predictive Biomarkers.Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers.Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.

P2860

Q26741977-65854DE1-D348-4E97-9B95-963DF6FF7DD4 Q28068378-2DC3F0D6-A238-4A76-B5F0-A12EFF8A8341 Q28072131-E8328D59-0A35-4116-98C9-949B01B59CA2 Q28080312-FE287DCE-E2E1-4F11-891D-E7F61C4E398F Q28276800-67D44B91-5F56-4C1B-973F-A1A532E88F0D Q30491565-318419B5-3236-4747-A122-090B53B6ED0B Q30827633-E40CE4E3-0685-4B0F-8753-39DC8A1A32CF Q30828860-0F0761E4-B1B4-4A4A-AA1E-3AB2C68E879A Q33564364-412839DE-7F08-42F5-816D-E05CD0D9E823 Q33593865-A83F5023-8488-42B0-88C8-EB7849CFF4D7 Q33827997-B0430A60-4637-4FC0-AED1-F35D7B767451 Q34047878-468F8FDA-4A34-45DA-8BD7-F7A4ADFB7624 Q34553167-D4AEED19-E48C-4D8E-909D-49E086D0E1B4 Q36281920-7865A254-1389-494D-A5EF-D785A2F67A2E Q37058104-5DBDCACD-1FE5-441C-A0A8-AEAB208FE734 Q37294760-4B1D5BD6-0876-4CA2-9B56-DDE173C14513 Q37395790-EEA6768D-EEAA-45B4-AD69-F4D1347549BF Q37509216-336BDBFA-53CB-4EE6-9D8F-F352CA41DA66 Q37566921-2764B57B-04B7-4CE9-85B1-AA957D070366 Q37576835-8B3CAD88-F586-48DE-B2A1-3493D9119593 Q37658246-794FE7EC-6231-420F-952A-4575B031F73D Q37713393-58032860-A928-43AF-BBEA-BE2242F8CAA2 Q37741606-6B72C371-1986-4B1C-8570-DCC1EA55CF43 Q38600697-C2070F12-083A-4217-8253-65CA0D03D1CA Q38615436-408A771C-12E6-46C6-9FDF-263467F8582B Q38640263-BDA9D940-7780-44E6-8FF7-045998794295 Q38640444-DFB43B29-D4E6-4D9C-AC58-FEE6F1D6E197 Q38661895-083196B5-E90D-4060-A9FC-ABDA82006DAE Q38666256-9B8F5EEA-12F0-4470-B2BB-397A7BBB6014 Q38666304-8C7C12EC-5AB6-494C-9948-8047D30061F1 Q38702393-6EBDAA16-9705-41A0-82E5-421B0E6929CD Q38754498-BBAD3570-CFA4-4656-B6BF-C020CA1BFA9F Q38768392-0B56D6A9-2C0C-43FC-ADB8-3E4953F61F19 Q38789518-78E4E181-8B90-4BCF-AC21-DD6CC5B4E14C Q38828829-9DC43721-EF5C-4C84-A974-CE11E9F2DFF0 Q38858256-60CF6D31-2318-4C45-B142-34CEABC1DD61 Q38861769-5282B6F0-3B93-48C7-A831-9D502843AF7A Q38890450-9FEF046D-3BAA-424B-A00D-0CE057E26497 Q38913549-43CD3961-65A6-4122-954A-C9C823CC0B68 Q38945853-1EFD94CA-1D67-4796-812E-7E347B8C628A

P2860

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

http://www.wikidata.org/entity/Q36951727

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

@en

type

label

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

@en

prefLabel

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

@en

P1433

Q36951727-56192F48-438C-41FC-AE3E-5BE5989EA2C9

P1476

Q36951727-1B1D48B6-DC73-44A2-BB9F-59B8ABA17AC0

P2093

Q36951727-01681321-E0B5-4F29-939C-95AE70009936

Q36951727-01DBF5DD-4D6F-41E1-884B-53E577E52773

Q36951727-155925DB-91D5-4395-8457-228C6A924108

Q36951727-1B8F773E-DAF1-487F-8C92-33950DB01036

Q36951727-1FCB7EB3-393C-4F6C-9D79-3A5BFA88CD28

Q36951727-2C3A0B4E-0ED7-46CE-9336-981DA4648C38

Q36951727-39642240-E679-405C-8EB2-A3C722712C46

Q36951727-3AC76088-A7C6-45E9-BE4D-5B3DB3452F6A

Q36951727-4671D0BD-BE03-4A5F-9869-C102244FE94F

Q36951727-5B9E85BB-C7D8-4F3C-A19E-80B798BCBF79

P2860

Q36951727-03C37844-644D-4A32-A2DA-1744A08E3DC5

Q36951727-1485F448-B2A0-45AB-8B03-ADB3D5F52B01

Q36951727-153FE054-B6D2-4258-B063-BAC17F8764F6

Q36951727-16324949-7CB1-46D0-8484-7BC37293D2C9

Q36951727-1C1220B7-8497-4925-AEA8-27B1D03905F2

Q36951727-33024B6F-7979-4192-85AE-C3EFF16F3891

Q36951727-3610939C-121C-40F3-8AA6-6899803E8222

Q36951727-4179D4EC-3BEB-45C7-AE80-980C038A609E

Q36951727-5937BD83-1178-4024-B6F0-500637553B95

Q36951727-5B09ED28-ECB1-48B6-8E1E-F44093DC5825

P304

Q36951727-13D9B1B3-0EDC-4B1D-A7F5-EDDD4C128370

P31

Q36951727-87931338-3F80-4C18-B954-8EF11F81DFC7

P356

Q36951727-595E7F4B-EBD6-4B7C-9E0A-B3AB8303C8F9

P407

Q36951727-7F9AB7F8-EA12-4CB0-8DAA-2484DE02ABF0

P433

Q36951727-148DF157-64BA-43DA-9BFE-47CD73D05138

P478

Q36951727-CFFDC9CB-6FCC-4206-AC4B-1CE492E264BE

P50

Q36951727-A0C2757D-C6CF-49E0-BD4B-E2C8829781F1

P577

Q36951727-A269EF47-213D-4084-B04B-FE9460BED9F0

P698

Q36951727-7C507A95-1DEF-4D9B-9F1F-088206328D66

P932

Q36951727-B02895AE-9FA8-4B21-BF1C-C31F430CF492

P356

P1433

Journal of Clinical Investigation

P1476

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

@en

P2093

Barbara Pender

http://www.w3.org/2001/XMLSchema#string

Brent Wood

http://www.w3.org/2001/XMLSchema#string

Cameron J Turtle

http://www.w3.org/2001/XMLSchema#string

Carolina Berger

http://www.w3.org/2001/XMLSchema#string

Cecilia Yeung

http://www.w3.org/2001/XMLSchema#string

Colette Chaney

http://www.w3.org/2001/XMLSchema#string

Daniel Li

http://www.w3.org/2001/XMLSchema#string

Daniel Sommermeyer

http://www.w3.org/2001/XMLSchema#string

Emily Robinson

http://www.w3.org/2001/XMLSchema#string

Jianhong Cao

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

A human memory T cell subset with stem cell-like properties

Chimeric antigen receptor T cells for sustained remissions in leukemia

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells

Current concepts in the diagnosis and management of cytokine release syndrome.

P304

2123-2138

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI85309

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P50

David G. Maloney

P577

2016-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27111235

http://www.w3.org/2001/XMLSchema#string

P932

4887159

http://www.w3.org/2001/XMLSchema#string